Hartwig Medical Foundation Adopts Ultima Genomics' UG200 to Scale Oncology Genomics
Event summary
- Hartwig Medical Foundation will adopt Ultima Genomics' UG200 sequencing system to expand its whole-genome sequencing (WGS) capabilities in oncology care.
- The collaboration will focus on validating and implementing Ultima's ppmSeq technology for monitoring minimal residual disease (MRD) with single-digit part-per-million sensitivity.
- Ultima's Solaris 2.0 workflows, featuring isothermal amplification and standard laboratory automation, aim to reduce operational complexity and cost.
- Hartwig and Ultima will collaborate on end-to-end workflows, including extending Hartwig's open-source cancer genomics tools (OncoAnalyser) to support Ultima data.
The big picture
This collaboration underscores the growing importance of whole-genome sequencing in oncology, as cost and operational barriers are addressed. The partnership aims to make WGS more accessible and scalable, potentially transforming cancer diagnostics and monitoring. The focus on MRD monitoring with ppmSeq technology highlights the shift toward more precise and longitudinal disease management in oncology care.
What we're watching
- Clinical Validation
- Whether Hartwig and Ultima can demonstrate the clinical utility and health-economic value of WGS-based disease monitoring in Dutch oncology care.
- Technology Scaling
- The pace at which Ultima's UG200 and Solaris 2.0 workflows can be deployed in clinical laboratory settings globally.
- Market Adoption
- How quickly the broader clinical genomics community can implement Ultima's technology in-house, supported by Hartwig's open-source tools.
Related topics